Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Net Margin (2016 - 2025)

Historic Net Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 92.91%.

  • Lineage Cell Therapeutics' Net Margin fell 135000.0% to 92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 296.07%, marking a year-over-year decrease of 661600.0%. This contributed to the annual value of 195.62% for FY2024, which is 445000.0% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Net Margin of 92.91% as of Q3 2025, which was down 135000.0% from 698.95% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Net Margin ranged from a high of 56.02% in Q4 2021 and a low of 969.73% during Q2 2021
  • Its 5-year average for Net Margin is 313.58%, with a median of 225.77% in 2023.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Net Margin skyrocketed by 12693600bps in 2021, and later tumbled by -3704800bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Net Margin (Quarter) stood at 56.02% in 2021, then plummeted by -493bps to 332.22% in 2022, then surged by 32bps to 225.77% in 2023, then surged by 50bps to 113.32% in 2024, then grew by 18bps to 92.91% in 2025.
  • Its Net Margin was 92.91% in Q3 2025, compared to 698.95% in Q2 2025 and 401.26% in Q1 2025.